Multicenter Phase 2 Study of Combination Therapy with Ruxolitinib and Danazol in Patients with Myelofibrosis

The investigators conducted a phase II clinical trial evaluating the efficacy and tolerability of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Although combination therapy did not lead to increased hematologic response, hematologic stabilization was observed and may be clinically useful.

 Leuk Res

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.